Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

Strasbourg (France), February 6, 2025, 5:45 p.m. CET — Transgene(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer,confirms that, in accordance with the provisions of the Attractiveness Act(“ Loi d'Attractivité ” – French Law No. 2024-537 of June 13, 2024),its shares are eligible for inclusion in the PEA-PME investment scheme*.As a result, Transgene (TNG) shares can be included or retained within this savings...

Illkirch Graffenstaden, 06/02/2025 (informazione.news - comunicati stampa - economia)

— (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, (“ ” – French Law No. 2024-537 of June 13, 2024), As a result, Transgene (TNG) shares can be included or retained within this savings plan, which is designed to support the financing of small and medium-sized enterprises (“ ”, PME) and intermediate-sized enterprises (“ ”, ETI), while benefiting from the same tax advantages as traditional “ ” investment scheme (PEA).

Tax advantages offered by PEA-PME and PEA are only available to French residents.

***

Attachment